Vcanbio Cell & Gene Engineering Corp Ltd - Asset Resilience Ratio

Latest as of March 2026: 2.86%

Vcanbio Cell & Gene Engineering Corp Ltd (600645) has an Asset Resilience Ratio of 2.86% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600645 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥150.61 Million
≈ $22.04 Million USD Cash + Short-term Investments

Total Assets

CN¥5.27 Billion
≈ $770.45 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (1996–2025)

This chart shows how Vcanbio Cell & Gene Engineering Corp Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Vcanbio Cell & Gene Engineering Corp Ltd (600645) total assets.

Liquid Assets Composition Over Time

This chart breaks down Vcanbio Cell & Gene Engineering Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Vcanbio Cell & Gene Engineering Corp Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥150.61 Million 2.86%
Total Liquid Assets CN¥150.61 Million 2.86%

Asset Resilience Insights

  • Limited Liquidity: Vcanbio Cell & Gene Engineering Corp Ltd maintains only 2.86% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vcanbio Cell & Gene Engineering Corp Ltd Industry Peers by Asset Resilience Ratio

Compare Vcanbio Cell & Gene Engineering Corp Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Abivax SA
PA:ABVX
Biotechnology 2.58%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%
Pulike Biological Engineering
SHG:603566
Biotechnology 17.82%
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 14.00%
NEWRON PHARMACEUT. EO-20
XETRA:NP5
Biotechnology 41.67%
Upstream Bio, Inc.
NASDAQ:UPB
Biotechnology 64.70%

Annual Asset Resilience Ratio for Vcanbio Cell & Gene Engineering Corp Ltd (1996–2025)

The table below shows the annual Asset Resilience Ratio data for Vcanbio Cell & Gene Engineering Corp Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 13.45% CN¥712.05 Million
≈ $104.20 Million
CN¥5.29 Billion
≈ $774.42 Million
+5.24pp
2019-12-31 8.22% CN¥401.67 Million
≈ $58.78 Million
CN¥4.89 Billion
≈ $715.35 Million
+7.75pp
2017-12-31 0.47% CN¥14.00 Million
≈ $2.05 Million
CN¥3.00 Billion
≈ $438.99 Million
-3.83pp
2016-12-31 4.30% CN¥129.10 Million
≈ $18.89 Million
CN¥3.00 Billion
≈ $439.53 Million
+4.30pp
2015-12-31 0.00% CN¥4.25K
≈ $621.91
CN¥2.82 Billion
≈ $412.09 Million
-15.20pp
2014-12-31 15.20% CN¥367.39 Million
≈ $53.76 Million
CN¥2.42 Billion
≈ $353.67 Million
+9.70pp
2010-12-31 5.50% CN¥42.45 Million
≈ $6.21 Million
CN¥771.69 Million
≈ $112.92 Million
+0.65pp
2008-12-31 4.85% CN¥31.61 Million
≈ $4.63 Million
CN¥651.74 Million
≈ $95.37 Million
+1.13pp
2007-12-31 3.72% CN¥21.90 Million
≈ $3.20 Million
CN¥588.65 Million
≈ $86.14 Million
+3.71pp
2006-12-31 0.01% CN¥50.00K
≈ $7.32K
CN¥579.39 Million
≈ $84.78 Million
-0.22pp
2003-12-31 0.23% CN¥1.45 Million
≈ $212.24K
CN¥636.09 Million
≈ $93.08 Million
-0.12pp
2002-12-31 0.35% CN¥1.99 Million
≈ $290.86K
CN¥567.42 Million
≈ $83.03 Million
-3.41pp
2001-12-31 3.76% CN¥29.35 Million
≈ $4.30 Million
CN¥781.36 Million
≈ $114.34 Million
-1.47pp
2000-12-31 5.23% CN¥35.45 Million
≈ $5.19 Million
CN¥678.36 Million
≈ $99.26 Million
+1.14pp
1999-12-31 4.09% CN¥26.97 Million
≈ $3.95 Million
CN¥659.36 Million
≈ $96.49 Million
+2.53pp
1998-12-31 1.56% CN¥10.50 Million
≈ $1.54 Million
CN¥673.16 Million
≈ $98.50 Million
+0.67pp
1997-12-31 0.89% CN¥5.37 Million
≈ $785.60K
CN¥606.51 Million
≈ $88.75 Million
-1.47pp
1996-12-31 2.36% CN¥10.17 Million
≈ $1.49 Million
CN¥431.22 Million
≈ $63.10 Million
--
pp = percentage points

About Vcanbio Cell & Gene Engineering Corp Ltd

SHG:600645 China Biotechnology
Market Cap
$1.32 Billion
CN¥9.03 Billion CNY
Market Cap Rank
#7807 Global
#1770 in China
Share Price
CN¥19.29
Change (1 day)
+1.26%
52-Week Range
CN¥16.74 - CN¥32.94
All Time High
CN¥68.93
About

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more